| Systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages in 28 European and Western Asian countries T Bochenek, V Abilova, A Alkan, B Asanin, I de Miguel Beriain, Z Besovic, ... Frontiers in pharmacology 8, 942, 2018 | 118 | 2018 |
| Pricing and reimbursement of biosimilars in Central and Eastern European countries P Kawalec, E Stawowczyk, T Tesar, J Skoupa, A Turcu-Stiolica, ... Frontiers in pharmacology 8, 288, 2017 | 77 | 2017 |
| The effectiveness of daily SMS reminders in pharmaceutical care of older adults on improving patients’ adherence to antihypertensive medication (SPPA): study protocol for a … Z Haramiova, M Stasko, M Hulin, T Tesar, M Kuzelova, DM Morisky Trials 18, 1-15, 2017 | 49 | 2017 |
| Pharmaceutical regulation in Central and Eastern European countries: a current review P Kawalec, T Tesar, L Vostalova, P Draganic, M Manova, A Savova, ... Frontiers in pharmacology 8, 892, 2017 | 45 | 2017 |
| Patient access, unmet medical need, expected benefits, and concerns related to the utilisation of biosimilars in Eastern European countries: a survey of experts A Inotai, M Csanadi, G Petrova, M Dimitrova, T Bochenek, T Tesar, K York, ... BioMed Research International 2018 (1), 9597362, 2018 | 42 | 2018 |
| Reimbursement legislations and decision making for orphan drugs in Central and Eastern European countries KP Malinowski, P Kawalec, W Trabka, M Czech, G Petrova, M Manova, ... Frontiers in pharmacology 10, 487, 2019 | 27 | 2019 |
| Policy practices to maximise social benefit from biosimilars A Inotai, M Csanádi, D Vitezic, I Francetic, T Tesar, T Bochenek, ... J Bioequiv Availab 9 (4), 467-72, 2017 | 25 | 2017 |
| The implications of external price referencing on pharmaceutical list prices in Europe M Csanádi, Z Kaló, CPJ Prins, E Grélinger, AM Kiss, FU Fricke, L Fuksa, ... Health Policy and Technology 7 (3), 243-250, 2018 | 24 | 2018 |
| Patient‐related characteristics associated with non‐persistence with statin therapy in elderly patients following an ischemic stroke M Wawruch, D Zatko, G Wimmer Jr, J Luha, V Hricak Jr, J Murin, ... Pharmacoepidemiology and drug safety 26 (2), 201-207, 2017 | 24 | 2017 |
| Potential cost-savings from the use of the biosimilars in Slovakia T Tesar, P Golias, Z Kobliskova, M Wawruch, P Kawalec, A Inotai Frontiers in Public Health 8, 431, 2020 | 18 | 2020 |
| Comparative analysis of legislative requirements about patients' access to biotechnological drugs for rare diseases in Central and Eastern European Countries M Kamusheva, M Manova, AT Savova, GI Petrova, K Mitov, A Harsányi, ... Frontiers in pharmacology 9, 795, 2018 | 17 | 2018 |
| Introduction of health technology assessment for medicines in Slovakia T Tesar, A Hloska, M Wawruch, L Lehocka, M Snopkova, L Masarykova International Journal of Technology Assessment in Health Care 33 (3), 345-349, 2017 | 17 | 2017 |
| How changes in reimbursement practices influence the financial sustainability of medicine policy: lessons learned from Slovakia T Tesar, B Obsitnik, Z Kaló, FB Kristensen Frontiers in Pharmacology 10, 664, 2019 | 16 | 2019 |
| Factors influencing non-persistence with antiplatelet medications in elderly patients after ischaemic stroke M Wawruch, D Zatko, G Wimmer, J Luha, L Kuzelova, P Kukumberg, ... Drugs & aging 33, 365-373, 2016 | 16 | 2016 |
| Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe KP Malinowski, P Kawalec, W Trąbka, C Sowada, G Petrova, M Manova, ... Orphanet journal of rare diseases 15, 1-13, 2020 | 15 | 2020 |
| Patient-associated characteristics influencing the risk for non-persistence with statins in older patients with peripheral arterial disease M Wawruch, G Wimmer, J Murin, M Paduchova, T Tesar, L Hlinkova, ... Drugs & Aging 36, 863-873, 2019 | 12 | 2019 |
| Cost-utility analysis of Heberprot-P as an add-on therapy to good wound care for patients in Slovakia with advanced diabetic foot ulcer T Tesar, L Szilberhorn, B Nemeth, B Nagy, M Wawruch, Z Kalo Frontiers in pharmacology 8, 946, 2017 | 10 | 2017 |
| Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries S Kovács, Z Kaló, R Daubner‐Bendes, K Kolasa, R Hren, T Tesar, ... Health Economics 31, 195-206, 2022 | 9 | 2022 |
| Age-related differences in non-persistence with statin treatment in patients after a transient ischaemic attack M Wawruch, D Zatko, G Wimmer, J Luha, S Wimmerova, P Matalova, ... Clinical Drug Investigation 37, 1047-1054, 2017 | 9 | 2017 |
| The impact of reimbursement practices on the pharmaceutical market for off-patent medicines in Slovakia T Tesar, P Golias, L Masarykova, P Kawalec, A Inotai Frontiers in pharmacology 12, 795002, 2021 | 8 | 2021 |
